|Alimera Sciences, Inc.|
6120 Windward Parkway
United States - Map
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The companys principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patients eye to a placement site that takes advantage of the eyes natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
|Mr. Charles Daniel Myers ,
Co-Founder, Chief Exec. Officer, Pres and Director
|Mr. Richard S. Eiswirth Jr.,
Chief Financial Officer, Principal Accounting Officer, Chief Operating Officer, VP, Treasurer and Sec.
|Dr. Kenneth Green Ph.D.,
Chief Scientific Officer and Sr. VP
|Mr. David R. Holland ,
Co-Founder and Sr. VP of Sales & Marketing
|Ms. Susan H. Caballa ,
Sr. VP of Regulatory & Medical Affairs
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|